Cel Sci (CVM) Net Equity Issued and Repurchased (2011 - 2026)
Cel Sci (CVM) posted Net Equity Issued and Repurchased of $200000.0 for Q1 2026, down 98.73% sequentially from $15.7 million in Q3 2025, and down 90.48% YoY from $2.1 million in Q1 2025.
Cel Sci (CVM) Net Equity Issued and Repurchased (2011 - 2026) Analysis & Trends
Cel Sci has reported Net Equity Issued and Repurchased for 14 years, with the latest figure at $200000.0 in Q1 2026.
- Quarterly Net Equity Issued and Repurchased fell 90.48% year-over-year to $200000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.0 million (changed 0.48% YoY) and the FY2025 annual result came in at $28.3 million, up 20.0% from the prior year.
- Net Equity Issued and Repurchased slipped to $200000.0 in Q1 2026 per CVM's latest filing, from $15.7 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $15.7 million in Q3 2025 and troughed at -$13.6 million in Q1 2022.
- A 5-year average of $4.2 million and a median of $5.0 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
- The sharpest annual moves came in 2024 and 2026: Net Equity Issued and Repurchased soared 116.9% in 2024, then plunged 90.48% in 2026.
- Over 5 years, Net Equity Issued and Repurchased stood at -$13.6 million in 2022, then jumped by 136.62% to $5.0 million in 2023, then gained by 0.41% to $5.0 million in 2024, then soared by 214.6% to $15.7 million in 2025, then sank by 98.73% to $200000.0 in 2026.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $200000.0, $15.7 million, and $2.1 million for Q1 2026, Q3 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Sep 30, 2025 | 15.73 Mn |
| Sep 30, 2025 | 15.73 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 10.85 Mn |
| Sep 30, 2024 | 10.85 Mn |
| Mar 31, 2024 | 7.75 Mn |
| Mar 31, 2024 | 7.75 Mn |
| Dec 31, 2023 | 4.98 Mn |
| Dec 31, 2023 | 4.98 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Mar 31, 2022 | -13.60 Mn |
| Mar 31, 2022 | -13.60 Mn |
| Dec 31, 2021 | 13.60 Mn |
| Dec 31, 2021 | 13.60 Mn |